| Dart Mining NL (DTM) ORDINARY FULLY PAID |
Materials |
$4 |
Continued Success at Rushworth
|
13 Aug 2024 9:20AM |
$0.014 |
$0.004 |
fallen by
75%
|
|
DTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Dart Mining NL has received positive results from Phase 2 diamond drilling at the Rushworth Gold Project.
- The project is located in the historic Rushworth Goldfield with a focus on shallow historic development and limited deeper drill testing.
- Highlights from the drilling results include SWDD005 intersecting 1.2m at 4.5g/t Au from 19.9m downhole.
- Phase 2 drilling validates the company's mineral systems model and exploration strategy.
- Drilling at Phoenix Reef has completed 2 out of 6 planned holes targeting repeating thrust faults at depth.
- Gold mineralisation is associated with sulphide mineralisation surrounding thrust fault structures.
- The Rushworth goldfield features three main types of structural architecture: thrust hosted quartz veins, North-South veins, and saddle reefs.
- Dart Mining aims to further develop the project through continued exploration and drill testing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$732 |
Monthly Net Tangible Asset Backing 31 July 2024
|
13 Aug 2024 9:20AM |
$2.250 |
$2.270 |
risen by
0.89%
|
|
| Australian Vanadium Limited (AVL) ORDINARY FULLY PAID |
Materials |
$78 |
AVL Receives $2.6m R&D Refund for 2022/23 Tax Year
|
13 Aug 2024 9:19AM |
$0.016 |
$0.009 |
fallen by
43.75%
|
|
| Volt Resources Limited (VRC) ORDINARY FULLY PAID |
Materials |
$19 |
Trading Halt
|
13 Aug 2024 9:19AM |
$0.003 |
$0.004 |
risen by
33.33%
|
|
VRC - Price-sensitive ASX Announcement
Full Release
Key Points
- Volt Resources Limited requested a trading halt.
- The trading halt is pending an announcement regarding a capital raising.
- The request was made to the ASX.
- The trading halt is expected to be lifted upon the announcement or commencement of trading on 6 September 2021.
- The company is in compliance with Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$3 |
Hydrix Ventures reduces Avertix Medical to current valuation
|
13 Aug 2024 9:18AM |
$0.014 |
$0.012 |
fallen by
14.29%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Ventures reduced the book value of its investment in Avertix Medical by A$1.75 million.
- Avertix Medical completed a Series C venture capital raise and a 100-to-1 reverse stock split.
- The new stock price for Avertix Medical is US$9.27 per share.
- Hydrix Ventures now holds 10,000 shares valued at approximately A$0.14 million.
- Hydrix Ventures initially invested in Avertix Medical for 4.6% equity at US$0.5 million in March 2020.
- Avertix Medical closed a US$7.8 million Series B round in February 2023.
- Avertix Medical entered into a now-terminated agreement to merge with BioPlus Acquisition Corp in May 2023.
- Hydrix Ventures' total investment portfolio value is now A$3.41 million.
- Hydrix is a technology innovation company focusing on enhancing health, safety, and well-being.
- The announcement was authorized for release by the Board of Directors of Hydrix Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$35 |
LTP Secures Global CoDevelopment Agreement with Aptar Pharma
|
13 Aug 2024 9:17AM |
$0.965 |
$0.310 |
fallen by
67.88%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Ltd and Aptar Pharma have entered into a Co-Development Agreement for SPONTAN for global markets.
- The primary goal is the commercialisation of SPONTAN in the USA and other key markets.
- The Agreement combines LTR’s pharmaceutical development capabilities with Aptar Pharma’s expertise in nasal spray technology.
- SPONTAN Nasal Spray application will be filed in the US via the FDA’s 505(b)(2) expedited regulatory pathway.
- The Agreement grants LTR Pharma access to Aptar Pharma’s comprehensive regulatory, analytical testing, and human factor services.
- A shared goal is to focus on market establishment and expansion, targeting commercialisation in the USA and other key markets.
- LTR Pharma recently completed a successful clinical trial comparing SPONTAN nasal spray and Levitra® tablets.
- SPONTAN achieved rapid absorption and a faster onset of action compared to oral PDE5 inhibitors.
- Medical providers in Australia have started prescribing SPONTAN under the TGA Special Access Scheme.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$173 |
Update - Notification of buy-back - CEH
|
13 Aug 2024 9:17AM |
$0.500 |
$0.400 |
fallen by
20%
|
|
| Ansarada Group Limited (AND) ORDINARY FULLY PAID |
Information Technology |
- |
FY24 Results Presentation
|
13 Aug 2024 9:16AM |
$2.480 |
$2.490 |
risen by
0.40%
|
|
AND - Price-sensitive ASX Announcement
Full Release
Key Points
- Ansarada reported a 30% increase in customer growth, ending the period with 13,366 customers.
- The company achieved total revenue of $56.7 million in FY24, up 10% year-over-year.
- Adjusted EBITDA was $11.1 million with a 20% margin.
- Annual recurring revenue (ARR) grew 22% year-over-year to $14.7 million.
- Cash flow from operations was positive at $17.3 million, with a net cash balance of $30.5 million and zero debt by the end of FY24.
- International revenue increased by 10% year-over-year, contributing 43% of total revenue.
- Revenue from the digital acquisition channel grew from 23% to 45% of total revenue in FY24.
- The company maintained a high gross margin of 96% year-over-year.
- Focus on enterprise contracts led to a higher proportion of recurring revenue.
- Investment in product, design, and technology continued with a focus on innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$171 |
NDO Investor briefing for 2024 Half-Year Results
|
13 Aug 2024 9:16AM |
$0.850 |
$0.750 |
fallen by
11.76%
|
|
| Ansarada Group Limited (AND) ORDINARY FULLY PAID |
Information Technology |
- |
FY24 Appendix 4E and Unaudited Annual Report
|
13 Aug 2024 9:15AM |
$2.480 |
$2.490 |
risen by
0.40%
|
|
AND - Price-sensitive ASX Announcement
Full Release
Key Points
- Ansarada Group Limited announced its FY24 Appendix 4E and Unaudited Annual Report.
- Ansarada reported a revenue of $46.5 million, reflecting a 12% year-on-year growth.
- The company experienced a net loss after tax of $9.2 million, which includes a non-cash impairment charge of $3.8 million.
- EBITDA (excluding significant items) was reported at $2.1 million.
- The company's cash balance as of June 30, 2024, was $18.4 million.
- Ansarada's Board decided not to declare a final dividend for FY24.
- The report includes updates on key strategies, market conditions, and operational highlights.
- Ansarada highlighted significant investments in product development and marketing to drive future growth.
- The company maintained a strong focus on customer acquisition, with a notable increase in new clients.
- The report outlines the impact of macroeconomic conditions and competitive pressures on performance.
- Ansarada plans to continue its focus on expanding its market presence and enhancing its product offerings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Incitec Pivot Limited (IPL) ORDINARY FULLY PAID |
Materials |
$4,827 |
Update - Notification of buy-back - IPL
|
13 Aug 2024 9:15AM |
$2.930 |
$2.590 |
fallen by
11.60%
|
|
| FINEOS Corporation Holdings PLC (FCL) CHESS DEPOSITARY INTERESTS 1:1 |
Information Technology |
$711 |
Half Year Result Release Date and Conference Call Details
|
13 Aug 2024 9:14AM |
$1.645 |
$2.100 |
risen by
27.66%
|
|
| ikeGPS Group Limited (IKE) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$139 |
Annual Meeting and Closing Date for Director Nominations
|
13 Aug 2024 9:14AM |
$0.620 |
$0.865 |
risen by
39.52%
|
|
| IXUP Limited (IXU) ORDINARY FULLY PAID |
Information Technology |
- |
Ontario Contract Starts, Triggers 1st Revenue in Nth America
|
13 Aug 2024 9:14AM |
$0.028 |
$0.009 |
fallen by
67.86%
|
|
IXU - Price-sensitive ASX Announcement
Full Release
Key Points
- Ontario contract commences triggering first revenues in North America for IXUP.
- First revenues earned by joint venture with IXUP’s North American partner IC360.
- Establishment of a North American operating division for IXUP.
- Contract involves centralized self-exclusion (CSE) register for the Province of Ontario.
- Total contract value estimated to be over A$10 million over an initial 5-year term.
- Revenues are from substantial up-front build activities representing ~25% of the overall contract value.
- Cash inflows from this contract will reduce IXUP’s monthly cash burn rate.
- Strategy being formed to pursue additional CSE contracts in North America.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Biopharma Limited (RGT) ORDINARY FULLY PAID |
Health Care |
$7 |
Trading Halt
|
13 Aug 2024 9:12AM |
$0.285 |
$0.094 |
fallen by
67.02%
|
|
RGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Argent BioPharma Limited (ASX: RGT) requested a trading halt pending an announcement.
- The trading halt is related to an application to be removed from the official list.
- The trading halt will last until the earlier of either the announcement release or the commencement of normal trading on 15 August 2024.
- The company is not aware of any reason why the trading halt should not be granted.
- The company is not aware of any additional information that needs to be disclosed to the market regarding the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$350 |
Update - Dividend/Distribution - AMH
|
13 Aug 2024 9:12AM |
$1.105 |
$1.110 |
risen by
0.45%
|
|
| Noviqtech Limited (NVQ) ORDINARY FULLY PAID |
Information Technology |
$6 |
Trading halt
|
13 Aug 2024 9:11AM |
$0.028 |
$0.025 |
fallen by
10.71%
|
|
NVQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Noviqtech Limited requested a trading halt effective immediately.
- The halt is pending an announcement regarding a capital raising.
- The trading halt will last until 15 August 2024 or until the announcement is released.
- No other reasons for the trading halt were provided by the company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$5 |
Update - Proposed issue of securities - PL3
|
13 Aug 2024 9:10AM |
$0.061 |
$0.045 |
fallen by
26.23%
|
|
| American West Metals Limited (AW1) ORDINARY FULLY PAID |
Materials |
$28 |
Clarification and Retraction Announcement
|
13 Aug 2024 9:10AM |
$0.140 |
$0.037 |
fallen by
73.57%
|
|
AW1 - Price-sensitive ASX Announcement
Full Release
Key Points
- American West Metals Limited (AW1) issued a clarification and retraction announcement.
- The announcement addresses errors in previous communications.
- AW1 provides corrected information regarding their projects and financial statements.
- The company aims to ensure transparent and accurate reporting to shareholders and stakeholders.
- Investors are advised to refer to the latest updated information provided by AW1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Torque Metals Limited (TOR) ORDINARY FULLY PAID |
Materials |
$34 |
Diamond Drilling Completed at Paris Gold Project
|
13 Aug 2024 9:07AM |
$0.105 |
$0.125 |
risen by
19.05%
|
|
TOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Diamond drill program successfully completed, comprising 1106m across the Paris (4 holes, 1006m) and HHH (1 hole, 100m) prospects.
- Program objective was to infill and extend high-grade mineralisation while obtaining structural, geotechnical, and density information to enhance and inform Torque’s maiden Mineral Resource Estimate.
- Core samples are now at the laboratory; assay results expected late August.
- Imminent ~7000m RC program is being fine-tuned with Program of Work (POW) approved.
- Paris is a shallow, high-grade, high-recovery (>96%) gold project located proximate to processing infrastructure and surrounded by producers such as Goldfields, Westgold, and Northern Star among others.
- Ongoing soil sampling across previously unexplored targets, with results expected by mid-September.
- Future activities include RC drill campaign of ~7000m, diamond drill results, RC drill results, and maiden Mineral Resource Estimate for Paris Gold Project.
- Highlight drilling results include 16m @ 4.19 g/t gold, 35m @ 14.12 g/t gold, and 39m @ 6.05 g/t gold among others.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Galena Mining Limited (G1A) ORDINARY FULLY PAID |
Materials |
- |
Corporate and Abra Operations Update
|
13 Aug 2024 9:05AM |
$0.059 |
$0.059 |
fallen by
0%
|
|
| Linius Technologies Limited (LNU) ORDINARY FULLY PAID |
Information Technology |
$6 |
Request for Extension of Voluntary Suspension
|
13 Aug 2024 9:05AM |
$0.002 |
$0.001 |
fallen by
50%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$700 |
Canaccord Genuity Growth Conference Presentation
|
13 Aug 2024 9:03AM |
$0.105 |
$1.200 |
risen by
1,042.86%
|
|
| Silk Logistics Holdings Limited (SLH) ORDINARY FULLY PAID |
Industrials |
$123 |
FY24 Full Year Results Webinar
|
13 Aug 2024 9:03AM |
$1.430 |
$1.510 |
risen by
5.59%
|
|
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$412 |
Weekly NTA 9 August 2024
|
13 Aug 2024 9:02AM |
$1.500 |
$1.820 |
risen by
21.33%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
